FFAR3 and Alzheimer disease: SCFAs might also impact AD indirectly through additional pathways via the regulation of intestinal gluconeogenesis by FFAR3 signalling, which affects the activity of the dorsal motor nucleus of the vagus, a structure with altered activity in PD and AD [8].